Molecular Modeling Targeting Transmembrane Serine Protease 2
(TMPRSS2) as an Alternative Drug Target Against Coronaviruses

Igor   José   dos Santos Nascimento; Edeildo    Ferreira   da Silva-Júnior; Thiago   Mendonça    de Aquino
doi:10.2174/1389450122666210809090909
Abstract

Since December 2019, the new Coronavirus disease (COVID-19) caused by the etiological agent SARS-CoV-2 has been responsible for several cases worldwide, becoming pandemic in March 2020. Pharmaceutical companies and academics have joined their efforts to discover new therapies to control the disease since there are no specific drugs to combat this emerging virus. Thus, several tar-gets have been explored; among them, the transmembrane protease serine 2 (TMPRSS2) has gained greater interest in the scientific community. In this context, this review will describe the importance of TMPRSS2 protease and the significant advances in virtual screening focused on discovering new inhibitors. In this review, it was observed that molecular modeling methods could be powerful tools in identifying new molecules against SARS-CoV-2. Thus, this review could be used to guide re-searchers worldwide to explore the biological and clinical potential of compounds that could be promising drug candidates against SARS-CoV-2, acting by inhibition of TMPRSS2 protein.
Keywords: TMPRSS2, SARS-CoV-2, structure-based drug discovery, virtual screening, drug repurposing, coronaviruses.
« Previous Next »
Graphical Abstract

[1] 
Goodarzi P, Mahdavi F, Mirzaei R, et al. Coronavirus disease 2019 (COVID-19): Immunological approaches and emerging pharmacologic treatments. Int Immunopharmacol  2020; 88106885
[http://dx.doi.org/10.1016/j.intimp.2020.106885] [PMID:  32795893] 
[2] 
Fuzimoto AD, Isidoro C. The antiviral and coronavirus-host protein pathways inhibiting properties of herbs and natural compounds - Additional weapons in the fight against the COVID-19 pandemic? J Tradit Complement Med  2020; 10(4): 405-19.
[http://dx.doi.org/10.1016/j.jtcme.2020.05.003] [PMID:  32691005] 
[3] 
Ullrich S, Nitsche C. The SARS-CoV-2 main protease as drug target. Bioorg Med Chem Lett  2020; 30(17)127377
[http://dx.doi.org/10.1016/j.bmcl.2020.127377] [PMID:  32738988] 
[4] 
Heimfarth L, Serafini MR, Martins-Filho PR, Quintans JSS, Quintans-Júnior LJ. Drug repurposing and cytokine management in response to COVID-19: A review. Int Immunopharmacol  2020; 88106947
[http://dx.doi.org/10.1016/j.intimp.2020.106947] [PMID:  32919216] 
[5] 
Wong GLH, Wong VWS, Thompson A, et al. Management of patients with liver derangement during the COVID-19 pandemic: An Asia-Pacific position statement. Lancet Gastroenterol Hepatol  2020; 5(8): 776-87.
[http://dx.doi.org/10.1016/S2468-1253(20)30190-4] [PMID:  32585136] 
[6] 
WHO Coronavirus Disease (COVID-19) Dashboard | WHO Coronavirus Disease (COVID-19) Dashboard. Available from:. https://covid19.who.int/
[7] 
Del Turco S, Vianello A, Ragusa R, Caselli C, Basta G. COVID-19 and cardiovascular consequences: Is the endothelial dysfunction the hardest challenge? Thromb Res  2020; 196: 143-51.
[http://dx.doi.org/10.1016/j.thromres.2020.08.039] [PMID:  32871306] 
[8] 
Raza SS, Khan MA. Mesenchymal stem cells: A new front emerge in covid19 treatment. Cytotherapy 2020.
[http://dx.doi.org/10.1016/j.jcyt.2020.07.002] 
[9] 
Pallanti S. Importance of SARs-Cov-2 anosmia: From phenomenology to neurobiology. Compr Psychiatry  2020; 100152184
[http://dx.doi.org/10.1016/j.comppsych.2020.152184] [PMID:  32422426] 
[10] 
Shi Y, Zhang X, Mu K, et al. D3Targets-2019-nCoV: A webserver for predicting drug targets and for multi-target and multi-site based virtual screening against COVID-19. Acta Pharm Sin B  2020; 10(7): 1239-48.
[http://dx.doi.org/10.1016/j.apsb.2020.04.006] [PMID:  32318328] 
[11] 
Kim JH, Marks F, Clemens JD. Looking beyond COVID-19 vaccine phase 3 trials. Nat Med  2021; 27(2): 205-11.
[http://dx.doi.org/10.1038/s41591-021-01230-y] [PMID:  33469205] 
[12] 
Forni G, Mantovani A. COVID-19 vaccines: Where we stand and challenges ahead. Cell Death Differ  2021; 28(2): 626-39.
[http://dx.doi.org/10.1038/s41418-020-00720-9] [PMID:  33479399] 
[13] 
Burgess RA, Osborne RH, Yongabi KA, et al. The COVID-19 vaccines rush: Participatory community engagement matters more than ever. Lancet  2021; 397(10268): 8-10.
[http://dx.doi.org/10.1016/S0140-6736(20)32642-8] [PMID:  33308484] 
[14] 
Chilamakuri R, Agarwal S. COVID-19: Characteristics and Therapeutics. Cells  2021; 10(2): 206.
[http://dx.doi.org/10.3390/cells10020206] [PMID:  33494237] 
[15] 
Ghaebi M, Osali A, Valizadeh H, Roshangar L, Ahmadi M. Vaccine development and therapeutic design for 2019-nCoV/SARS-CoV-2: Challenges and chances. J Cell Physiol  2020; 235(12): 9098-109.
[http://dx.doi.org/10.1002/jcp.29771] [PMID:  32557648] 
[16] 
Nascimento IJDS, de Aquino TM, Silva-júnior EF. Drug repurposing : A strategy for discovering inhibitors against emerging viral infections. Curr Med Chem  2021; 28(15): 2887-942.
[17] 
Lounnas V, Ritschel T, Kelder J, McGuire R, Bywater RP, Foloppe N. Current progress in structure-based rational drug design marks a new mindset in drug discovery. Comput Struct Biotechnol J  2013; 5e201302011
[http://dx.doi.org/10.5936/csbj.201302011] [PMID:  24688704] 
[18] 
José dos Santos Nascimento I, Mendonça de Aquino T, Fernando da Silva Santos-Júnior P, Xavier de Araújo-Júnior J, Ferreira da Silva-Júnior E. Molecular modeling applied to design of cysteine protease inhibitors - a powerful tool for the identification of hit compounds against neglected tropical diseases. Front Comput Chem  2020; 5: 63-110.
[19] 
Rognan D. The impact of in silico screening in the discovery of novel and safer drug candidates. Pharmacol Ther  2017; 175: 47-66.
[http://dx.doi.org/10.1016/j.pharmthera.2017.02.034] [PMID:  28223231] 
[20] 
van Montfort RLM, Workman P. Structure-based drug design: Aiming for a perfect fit. Essays Biochem  2017; 61(5): 431-7.
[http://dx.doi.org/10.1042/EBC20170052] [PMID:  29118091] 
[21] 
Faheem; Kumar, B.K.; Sekhar, K.V.G.C.; Kunjiappan, S.; Jamalis, J.; Balaña-Fouce, R.; Tekwani, B.L.; Sankaranarayanan, M. Druggable targets of sars-cov-2 and treatment opportunities for covid-19. Bioorg Chem  2020; 104104269
[22] 
Drożdżal S, Rosik J, Lechowicz K, et al. FDA approved drugs with pharmacotherapeutic potential for SARS-CoV-2 (COVID-19) therapy. Drug Resist Updat  2020; 53100719
[http://dx.doi.org/10.1016/j.drup.2020.100719] [PMID:  32717568] 
[23] 
Naqvi AAT, Fatima K, Mohammad T, et al. Insights into SARS-CoV-2 genome, structure, evolution, pathogenesis and therapies: Structural genomics approach. Biochim Biophys Acta Mol Basis Dis  2020; 1866(10)165878
[http://dx.doi.org/10.1016/j.bbadis.2020.165878] [PMID:  32544429] 
[24] 
Gil C, Ginex T, Maestro I, et al. COVID-19: Drug targets and potential treatments. J Med Chem  2020; 63(21): 12359-86.
[http://dx.doi.org/10.1021/acs.jmedchem.0c00606] [PMID:  32511912] 
[25] 
Pandey A, Nikam AN, Shreya AB, et al. Potential therapeutic targets for combating SARS-CoV-2: Drug repurposing, clinical trials and recent advancements. Life Sci  2020; 256117883
[http://dx.doi.org/10.1016/j.lfs.2020.117883] [PMID:  32497632] 
[26] 
Vallamkondu J, John A, Wani WY, et al. SARS-CoV-2 pathophysiology and assessment of coronaviruses in CNS diseases with a focus on therapeutic targets. Biochim Biophys Acta Mol Basis Dis  2020; 1866(10)165889
[http://dx.doi.org/10.1016/j.bbadis.2020.165889] [PMID:  32603829] 
[27] 
Khare P, Sahu U, Pandey SC, Samant M. Current approaches for target-specific drug discovery using natural compounds against SARS-CoV-2 infection. Virus Res  2020; 290198169
[http://dx.doi.org/10.1016/j.virusres.2020.198169] [PMID:  32979476] 
[28] 
Muralidar S, Ambi SV, Sekaran S, Krishnan UM. The emergence of COVID-19 as a global pandemic: Understanding the epidemiology, immune response and potential therapeutic targets of SARS-CoV-2. Biochimie  2020; 179: 85-100.
[http://dx.doi.org/10.1016/j.biochi.2020.09.018] [PMID:  32971147] 
[29] 
Tiwari V, Beer JC, Sankaranarayanan NV, Swanson-Mungerson M, Desai UR. Discovering small-molecule therapeutics against SARS-CoV-2. Drug Discov Today  2020; 25(8): 1535-44.
[http://dx.doi.org/10.1016/j.drudis.2020.06.017] [PMID:  32574699] 
[30] 
Kumar D, Chauhan G, Kalra S, Kumar B, Gill MS. A perspective on potential target proteins of COVID-19: Comparison with SARS-CoV for designing new small molecules. Bioorg Chem  2020; 104104326
[http://dx.doi.org/10.1016/j.bioorg.2020.104326] [PMID:  33142431] 
[31] 
Burdova A, Bouchal J, Tavandzis S, Kolar Z. TMPRSS2-ERG gene fusion in prostate cancer. Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub  2014; 158(4): 502-10.
[http://dx.doi.org/10.5507/bp.2014.065] [PMID:  25485532] 
[32] 
Strope JD, Pharm D. CHC, Figg WD. TMPRSS2: Potential biomarker for covid-19 outcomes. J Clin Pharmacol D  2020; 60(7): 801-7.
[http://dx.doi.org/10.1002/jcph.1641] [PMID:  32437018] 
[33] 
Helgeson BE, Tomlins SA, Shah N, et al. Characterization of TMPRSS2:ETV5 and SLC45A3: ETV5 gene fusions in prostate cancer. Cancer Res  2008; 68(1): 73-80.
[http://dx.doi.org/10.1158/0008-5472.CAN-07-5352] [PMID:  18172298] 
[34] 
Rubin MA, Chinnaiyan AM. Bioinformatics approach leads to the discovery of the TMPRSS2: ETS gene fusion in prostate cancer. Lab Invest  2006; 86(11): 1099-102.
[http://dx.doi.org/10.1038/labinvest.3700477] [PMID:  16983328] 
[35] 
Shen LW, Mao HJ, Wu YL, Tanaka Y, Zhang W. TMPRSS2: A potential target for treatment of influenza virus and coronavirus infections. Biochimie  2017; 142: 1-10.
[http://dx.doi.org/10.1016/j.biochi.2017.07.016] [PMID:  28778717] 
[36] 
Antalis TM, Bugge TH, Wu Q. Membrane-anchored serine proteases in health and disease  Elsevier Inc.. 2011; 99.
[http://dx.doi.org/10.1016/B978-0-12-385504-6.00001-4] 
[37] 
Fraser B, Beldar S, Hutchinson A, et al. Crystal structure of human tmprss2 in complex with nafamostat. Protein Data Bank 2021.
[38] 
van Dam PA, Huizing M, Mestach G, et al. SARS-CoV-2 and cancer: Are they really partners in crime? Cancer Treat Rev  2020; 89102068
[http://dx.doi.org/10.1016/j.ctrv.2020.102068] [PMID:  32731090] 
[39] 
Vargas-Alarcón G, Posadas-Sánchez R, Ramírez-Bello J. Variability in genes related to SARS-CoV-2 entry into host cells (ACE2, TMPRSS2, TMPRSS11A, ELANE, and CTSL) and its potential use in association studies. Life Sci  2020; 260118313
[http://dx.doi.org/10.1016/j.lfs.2020.118313] [PMID:  32835700] 
[40] 
Zhou QA, Kato-Weinstein J, Li Y, et al. Potential therapeutic agents and associated bioassay data for covid-19 and related human coronavirus infections. ACS Pharmacol Transl Sci  2020; 3(5): 813-34.
[http://dx.doi.org/10.1021/acsptsci.0c00074] [PMID:  33062950] 
[41] 
Xiu S, Dick A, Ju H, et al. Inhibitors of sars-cov-2 entry: Current and future opportunities. J Med Chem  2020; 63(21): 12256-74.
[42] 
Teralı K, Baddal B, Gülcan HO. Prioritizing potential ACE2 inhibitors in the COVID-19 pandemic: Insights from a molecular mechanics-assisted structure-based virtual screening experiment. J Mol Graph Model  2020; 100107697
[http://dx.doi.org/10.1016/j.jmgm.2020.107697] [PMID:  32739642] 
[43] 
Jankun J. Covid-19 pandemic; transmembrane protease serine 2 (tmprss2) inhibitors as potential drugs. Transl Univ Toledo J Med Sci  2020; 7: 1-5.
[http://dx.doi.org/10.46570/utjms.vol7-2020-361] 
[44] 
Bittmann S. COVID 19: Camostat and the role of serine protease entry inhibitor tmprss2. J Regen Biol Med  2020; 2: 1-2.
[45] 
Yamamoto M, Kiso M, Sakai-Tagawa Y, et al. The anticoagulant nafamostat potently inhibits sars-cov-2 s protein-mediated fusion in a cell fusion assay system and viral infection in vitro in a cell-type-dependent manner. Viruses  2020; 12(6): 12.
[http://dx.doi.org/10.3390/v12060629] [PMID:  32532094] 
[46] 
Hoffmann M, Schroeder S, Kleine-Weber H, Müller MA, Drosten C, Pöhlmann S. Nafamostat mesylate blocks activation of sars-coV-2: New treatment option for covid-19. Antimicrob Agents Chemother  2020; 64(6): 1-7.
[http://dx.doi.org/10.1128/AAC.00754-20] [PMID:  32312781] 
[47] 
Shrimp JH, Kales SC, Sanderson PE, Simeonov A, Shen M, Hall MD. An enzymatic tmprss2 assay for assessment of clinical candidates and discovery of inhibitors as potential treatment of covid-19 ACS Pharmacol Transl Sci  2020.
[48] 
Yamamoto M, Matsuyama S, Li X, et al. Identification of nafamostat as a potent inhibitor of middle east respiratory syndrome coronavirus s protein-mediated membrane fusion using the split-protein-based cell-cell fusion assay. Antimicrob Agents Chemother  2016; 60(11): 6532-9.
[http://dx.doi.org/10.1128/AAC.01043-16] [PMID:  27550352] 
[49] 
Kijewska M, Sharfalddin AA, Jaremko Ł, et al. Lossen rearrangement of p-toluenesulfonates of n-oxyimides in basic condition, theoretical study, and molecular docking. Front Chem  2021; 9662533
[http://dx.doi.org/10.3389/fchem.2021.662533] [PMID:  33937199] 
[50] 
Hughes JP, Rees S, Kalindjian SB, Philpott KL. Principles of early drug discovery. Br J Pharmacol  2011; 162(6): 1239-49.
[http://dx.doi.org/10.1111/j.1476-5381.2010.01127.x] [PMID:  21091654] 
[51] 
Zhao L, Ciallella HL, Aleksunes LM, Zhu H. Advancing computer-aided drug discovery (CADD) by big data and data-driven machine learning modeling. Drug Discov Today  2020; 25(9): 1624-38.
[http://dx.doi.org/10.1016/j.drudis.2020.07.005] [PMID:  32663517] 
[52] 
Surabhi S, Singh B. Computer aided drug design: An overview. J Drug Deliv Ther  2018; 8: 504-9.
[http://dx.doi.org/10.22270/jddt.v8i5.1894] 
[53] 
Mohs RC, Greig NH. Drug discovery and development: Role of basic biological research. Alzheimers Dement (N Y)  2017; 3(4): 651-7.
[http://dx.doi.org/10.1016/j.trci.2017.10.005] [PMID:  29255791] 
[54] 
Yu W, Jr ADM. Chapter 5 computer-aided drug design methodsAntibiot Methods Protoc.   2017; 1520: pp. 85-106.
[55] 
Njogu PM, Guantai EM, Pavadai E, Chibale K. Computer-aided drug discovery approaches against the tropical infectious diseases malaria, tuberculosis, trypanosomiasis, and leishmaniasis. ACS Infect Dis  2016; 2(1): 8-31.
[http://dx.doi.org/10.1021/acsinfecdis.5b00093] [PMID:  27622945] 
[56] 
Idris MO, Yekeen AA, Alakanse OS, Durojaye OA. Computer-aided screening for potential TMPRSS2 inhibitors: A combination of pharmacophore modeling, molecular docking and molecular dynamics simulation approaches. J Biomol Struct Dyn  2020; 1-19.
[http://dx.doi.org/10.1080/07391102.2020.1792346] [PMID:  32672528] 
[57] 
Li Q, Wang Z, Zheng Q, Liu S. Potential clinical drugs as covalent inhibitors of the priming proteases of the spike protein of SARS-CoV-2. Comput Struct Biotechnol J  2020; 18: 2200-8.
[http://dx.doi.org/10.1016/j.csbj.2020.08.016] [PMID:  32868983] 
[58] 
Elmezayen AD, Al-Obaidi A, Şahin AT, Yelekçi K. Drug repurposing for coronavirus (covid-19): In silico screening of known drugs against coronavirus 3cl hydrolase and protease enzymes. J Biomol Struct Dyn  2020; 1-13.
[http://dx.doi.org/10.1080/07391102.2020.1798812] [PMID:  32306862] 
[59] 
Huggins DJ. Structural analysis of experimental drugs binding to the SARS-CoV-2 target TMPRSS2. J Mol Graph Model  2020; 100107710
[http://dx.doi.org/10.1016/j.jmgm.2020.107710] [PMID:  32829149] 
[60] 
Batool M, Ahmad B, Choi S. A structure-based drug discovery paradigm. Int J Mol Sci  2019; 20(11): 20.
[http://dx.doi.org/10.3390/ijms20112783] [PMID:  31174387] 
[61] 
Muhammed MT, Aki-Yalcin E. Homology modeling in drug discovery: Overview, current applications, and future perspectives. Chem Biol Drug Des  2019; 93(1): 12-20.
[http://dx.doi.org/10.1111/cbdd.13388] [PMID:  30187647] 
[62] 
França TCC. Homology modeling: an important tool for the drug discovery. J Biomol Struct Dyn  2015; 33(8): 1780-93.
[http://dx.doi.org/10.1080/07391102.2014.971429] [PMID:  25266493] 
[63] 
Munsamy G, Soliman MES. Homology modeling in drug discovery-an update on the last decade. Lett Drug Des Discov  2017; 14.
[http://dx.doi.org/10.2174/1570180814666170110122027] 
[64] 
Cavasotto CN, Phatak SS. Homology modeling in drug discovery: Current trends and applications. Drug Discov Today  2009; 14(13-14): 676-83.
[http://dx.doi.org/10.1016/j.drudis.2009.04.006] [PMID:  19422931] 
[65] 
Sliwoski G, Kothiwale S, Meiler J, Lowe EW Jr. Computational methods in drug discovery. Pharmacol Rev  2013; 66(1): 334-95.
[http://dx.doi.org/10.1124/pr.112.007336] [PMID:  24381236] 
[66] 
Sousa SF, Cerqueira NM, Fernandes PA, Ramos MJ. Virtual screening in drug design and development. Comb Chem High Throughput Screen  2010; 13(5): 442-53.
[http://dx.doi.org/10.2174/138620710791293001] [PMID:  20236061] 
[67] 
Subramaniam S, Mehrotra M, Gupta D. Virtual high throughput screening (vHTS)--a perspective. Bioinformation  2008; 3(1): 14-7.
[http://dx.doi.org/10.6026/97320630003014] [PMID:  19052660] 
[68] 
Good AC, Krystek SR, Mason JS. High-throughput and virtual screening: Core lead discovery technologies move towards integration. Drug Discov Today  2000; 5(12)(Suppl. 1): 61-9.
[http://dx.doi.org/10.1016/S1359-6446(00)00015-5] [PMID:  11564568] 
[69] 
Bajorath J. Integration of virtual and high-throughput screening. Nat Rev Drug Discov  2002; 1(11): 882-94.
[http://dx.doi.org/10.1038/nrd941] [PMID:  12415248] 
[70] 
Kontoyianni M. Docking and virtual screening in drug discovery.   2017; pp. 255-66.
[http://dx.doi.org/10.1007/978-1-4939-7201-2_18] 
[71] 
Christoph G, Krishna P, Kendra E. L.; Marco, C.; Patrick D., F.; Zi-Fu, W.; Guilhem, T.; Shreya, P.; Alec, S.; Anthony, C.; Colin, H.; Minko, G.; Alexander, R.; Noam, L.; Erez, Y.; Roni, L.; Henry D., H.; Vedat, D.; Thanos D., H.; Konstantin, F.; Justin J., P.; Alexander, C.; Igor, D.; Alla, P.; Yurii, M.; Dmytro, R.; Olga, T.; Irina, Y.; Christian C., G.; Ryan, Y.; Dave, P.; Anders M., N.; Mark N., N.; Robert A., D.; Gerhard, W.; Jamie, K.; Haribabu, A. A multi-pronged approach targeting sars-cov-2 proteins using ultra-large virtual screening. ChemRxiv  2020; 2.
[72] 
Qing X, Lee XY, De Raeymaeker J, et al. Pharmacophore modeling: Advances, limitations, and current utility in drug discovery. J Receptor Ligand Channel Res  2014; 7: 81-92.
[73] 
Yang SY. Pharmacophore modeling and applications in drug discovery: Challenges and recent advances. Drug Discov Today  2010; 15(11-12): 444-50.
[http://dx.doi.org/10.1016/j.drudis.2010.03.013] [PMID:  20362693] 
[74] 
Schaller D, Šribar D, Noonan T, et al. Next generation 3d pharmacophore modeling. Wiley Interdiscip Rev Comput Mol Sci  2020; 10: 1-20.
[http://dx.doi.org/10.1002/wcms.1468] 
[75] 
Nguyen B. In silico pharmacophore study and structural optimization
 of nafamostat yield potentially novel transmembrane protease
 serine 2 (tmprss2) inhibitors which block the entry of sars-cov-2
 virus into human cells 2020; 2 
[76] 
Choudhary S, Silakari O. Scaffold morphing of arbidol (umifenovir) in search of multi-targeting therapy halting the interaction of sars-cov-2 with ace2 and other proteases involved in covid-19.  Elsevier B.V. 2020; p. 289.
[77] 
Kandeel M, Yamamoto M, Tani H, et al. Discovery of new fusion inhibitor peptides against SARS-CoV-2 by targeting the spike S2 subunit. Biomol Ther (Seoul)  2021; 29(3): 282-9.
[http://dx.doi.org/10.4062/biomolther.2020.201]] 
[78] 
Fernández-Prada C, Douanne N, Minguez-Menendez A, et al. Repurposed molecules: A new hope in tackling neglected infectious diseasesin silico drug design.  Elsevier 2019; pp. 119-60.
[http://dx.doi.org/10.1016/B978-0-12-816125-8.00005-5] 
[79] 
Andersen PI, Ianevski A, Lysvand H, et al. Discovery and development of safe-in-man broad-spectrum antiviral agents. Int J Infect Dis  2020; 93: 268-76.
[http://dx.doi.org/10.1016/j.ijid.2020.02.018] [PMID:  32081774] 
[80] 
Kuiken T, Fouchier R, Rimmelzwaan G, Osterhaus A. Emerging viral infections in a rapidly changing world. Curr Opin Biotechnol  2003; 14(6): 641-6.
[http://dx.doi.org/10.1016/j.copbio.2003.10.010] [PMID:  14662395] 
[81] 
Sahu NU, Shah CP, Machhar JS, Kharkar PS. Drug repurposing in search of anti-infectives: Need of the hour in the multidrug resistance era!in silico drug design.  Elsevier 2019; pp. 399-426.
[http://dx.doi.org/10.1016/B978-0-12-816125-8.00014-6] 
[82] 
Mercorelli B, Palù G, Loregian A. Drug repurposing for viral infectious diseases: How far are we? Trends Microbiol  2018; 26(10): 865-76.
[http://dx.doi.org/10.1016/j.tim.2018.04.004] [PMID:  29759926] 
[83] 
Siegelin MD, Schneider E, Westhoff M-A, Wirtz CR, Karpel-Massler G. Current state and future perspective of drug repurposing in malignant glioma. Semin Cancer Biol  2021; 68: 92-104.
[http://dx.doi.org/10.1016/j.semcancer.2019.10.018] [PMID:  31734137] 
[84] 
Gns HS, Gr S. An update on drug repurposing: Re-written saga ofthe drug’s fate  2019; 110: 700-16.
[85] 
Oprea TI, Bauman JE, Bologa CG, et al. Drug repurposing from an academic perspective. Drug Discov Today Ther Strateg  2011; 8(3-4): 61-9.
[http://dx.doi.org/10.1016/j.ddstr.2011.10.002] [PMID:  22368688] 
[86] 
Sonawane K, Barale SS, Dhanavade MJ, et al. Homology modeling and docking studies of TMPRSS2 with experimentally known inhibitors camostat mesylate, nafamostat and bromhexine hydrochloride to control SARS-coronavirus-2. ChemRxiv 2020.
[87] 
Wu C, Liu Y, Yang Y, et al. Analysis of therapeutic targets for SARS-CoV-2 and discovery of potential drugs by computational methods. Acta Pharm Sin B  2020; 10(5): 766-88.
[http://dx.doi.org/10.1016/j.apsb.2020.02.008] [PMID:  32292689] 
[88] 
Napolitano F, Gambardella G, Carrella D, Gao X, di Bernardo D. Computational drug repositioning and elucidation of mechanism
of action of compounds against SARS-CoV-2 arXiv preprint
arXiv:200407697, 2020.
[89] 
Mahdian S, Ebrahim-Habibi A, Zarrabi M. Drug repurposing using computational methods to identify therapeutic options for COVID-19. J Diabetes Metab Disord  2020; 19(2): 1-9.
[PMID:  32837954] 
[90] 
Mahmoud IS, Jarrar YB, Alshaer W, Ismail S. SARS-CoV-2 entry in host cells-multiple targets for treatment and prevention. Biochimie  2020; 175: 93-8.
[http://dx.doi.org/10.1016/j.biochi.2020.05.012] [PMID:  32479856] 
[91] 
Jaimes JA, Millet JK, Whittaker GR. Proteolytic cleavage of the
 sars-cov-2 spike protein and the role of the novel s1/s2 site iScience
2020; 23: 101212 
[92] 
Madadlou A. Food proteins are a potential resource for mining cathepsin L inhibitory drugs to combat SARS-CoV-2. Eur J Pharmacol  2020; 885173499
[http://dx.doi.org/10.1016/j.ejphar.2020.173499] [PMID:  32841639] 
[93] 
McInnes C. Virtual screening strategies in drug discovery. Curr Opin Chem Biol  2007; 11(5): 494-502.
[http://dx.doi.org/10.1016/j.cbpa.2007.08.033] [PMID:  17936059] 
[94] 
Cerqueira NMFSA, Gesto D, Oliveira EF, et al. Receptor-based virtual screening protocol for drug discovery. Arch Biochem Biophys  2015; 582: 56-67.
[http://dx.doi.org/10.1016/j.abb.2015.05.011] [PMID:  26045247] 
[95] 
Singh N, Decroly E, Khatib A-M, Villoutreix BO. Structure-based drug repositioning over the human TMPRSS2 protease domain: Search for chemical probes able to repress SARS-CoV-2 Spike protein cleavages. Eur J Pharm Sci  2020; 153105495
[http://dx.doi.org/10.1016/j.ejps.2020.105495] [PMID:  32730844] 
[96] 
Coban M, Morrison J, Freeman WS, Radisky E, Le Roch K, Caulfield T. Targeting Tmprss2, S-Protein:Ace2, and 3CLpro for synergetic inhibitory engagement. ChemRxiv 2020.
[97] 
Rensi S, Keys A, Lo Y-C, et al. Homology modeling of tmprss2 yields candidate drugs that may inhibit entry of sars-cov-2 into human cells. ChemRxiv 2020.
[98] 
Mulgaonkar NS, Wang H, Mallawarachchi S, Ruzek D, Martina B, Fernando S. Bcr-Abl tyrosine kinase inhibitor imatinib as a potential drug for covid-19. bioRxiv 2020.
[99] 
Baby K, Maity S, Mehta CH, Suresh A, Nayak UY, Nayak Y. SARS-CoV-2 entry inhibitors by dual targeting TMPRSS2 and ACE2: An in silico drug repurposing study. Eur J Pharmacol  2021; 896173922
[http://dx.doi.org/10.1016/j.ejphar.2021.173922] [PMID:  33539819] 
[100] 
Dwarka D, Agoni C, Mellem JJ, Soliman ME, Baijnath H. Identification of potential SARS-CoV-2 inhibitors from South African medicinal plant extracts using molecular modelling approaches. S Afr J Bot  2020; 133: 273-84.
[http://dx.doi.org/10.1016/j.sajb.2020.07.035] [PMID:  32839635] 
[101] 
Tahir Ul Qamar M, Alqahtani SM, Alamri MA, Chen LL. Structural basis of SARS-CoV-2 3CLpro and anti-COVID-19 drug discovery from medicinal plants. J Pharm Anal  2020; 10(4): 313-9.
[http://dx.doi.org/10.1016/j.jpha.2020.03.009] [PMID:  32296570] 
[102] 
Oladele JO, Ajayi EI, Oyeleke OM, et al. A systematic review on COVID-19 pandemic with special emphasis on curative potentials of Nigeria based medicinal plants. Heliyon  2020; 6(9)e04897
[http://dx.doi.org/10.1016/j.heliyon.2020.e04897] [PMID:  32929412] 
[103] 
Vivek-Ananth RP, Rana A, Rajan N, Biswal HS, Samal A. In silico identification of potential natural product inhibitors of human proteases key to sars-cov-2 infection. Molecules  2020; 25(17): 3822.
[http://dx.doi.org/10.3390/molecules25173822] [PMID:  32842606] 
[104] 
Yadav PK, Jaiswal A, Singh RK. In silico study on spice-derived antiviral phytochemicals against sars-cov-2 tmprss2 target 2020.
[105] 
Rahman N, Basharat Z, Yousuf M, Castaldo G, Rastrelli L, Khan H. Virtual screening of natural products against type ii transmembrane serine protease (tmprss2), the priming agent of coronavirus 2 (sars-cov-2). Molecules  2020; 25(10): 1-12.
[http://dx.doi.org/10.3390/molecules25102271] [PMID:  32408547] 
[106] 
 P., H.; A., F.. Exploring structurally diverse plant secondary metabolites
 as a potential source of drug targeting different molecular
 mechanisms of severe acute respiratory syndrome coronavirus-2
 (sars-cov-2) pathogenesis. An in silico Approach 2020; 2: 1-38.. 
[107] 
Dar NJ. MuzamilAhmad. Neurodegenerative diseases and Withania somnifera (L.): An update. J Ethnopharmacol  2020; 256112769
[http://dx.doi.org/10.1016/j.jep.2020.112769] [PMID:  32240781] 
[108] 
Vanden Berghe W, Sabbe L, Kaileh M, Haegeman G, Heyninck K. Molecular insight in the multifunctional activities of Withaferin A. Biochem Pharmacol  2012; 84(10): 1282-91.
[http://dx.doi.org/10.1016/j.bcp.2012.08.027] [PMID:  22981382] 
[109] 
Hassannia B, Logie E, Vandenabeele P, et al. From ayurvedic folk medicine to preclinical anti-cancer drug. Biochem Pharmacol  2020; 173113602
[http://dx.doi.org/10.1016/j.bcp.2019.08.004] [PMID:  31404528] 
[110] 
Kumar V, Dhanjal JK, Bhargava P, et al. Withanone and Withaferin-A are predicted to interact with transmembrane protease serine 2 (TMPRSS2) and block entry of SARS-CoV-2 into cells. J Biomol Struct Dyn  2020; 0: 1-13.
[http://dx.doi.org/10.1080/7391102.2020.1775704] [PMID:  32469279] 
[111] 
Chikhale RV, Gupta VK, Eldesoky GE, Wabaidur SM, Patil SA, Islam MA. Identification of potential anti-TMPRSS2 natural products through homology modelling, virtual screening and molecular dynamics simulation studies. J Biomol Struct Dyn  2020; 0: 1-16.
[http://dx.doi.org/10.1080/07391102.2020.1798813] [PMID:  32741259] 
[112] 
Dave GS, Rakholiya KD, Kaneria MJ, et al. High affinity interaction of solanum tuberosum and brassica juncea residue smoke water compounds with proteins involved in coronavirus infection. Phytother Res  2020; 34(12): 3400-10.
[113] 
Roomi M, Khan Y. Potential compounds for the inhibition of TMPRSS2. ChemRxiv 2020.
[114] 
Morais-Braga MFB, Carneiro JNP, Machado AJT, et al. Psidium guajava L., from ethnobiology to scientific evaluation: Elucidating bioactivity against pathogenic microorganisms. J Ethnopharmacol  2016; 194: 1140-52.
[http://dx.doi.org/10.1016/j.jep.2016.11.017] [PMID:  27845266] 
[115] 
Mgbeahuruike EE, Yrjönen T, Vuorela H, Holm Y. Bioactive compounds from medicinal plants: Focus on piper species. S Afr J Bot  2017; 112: 54-69.
[http://dx.doi.org/10.1016/j.sajb.2017.05.007] 
[116] 
De Jesus M, Gaza J, Junio HA, Nellas R. Molecular docking of secondary metabolites from Psidium Guajava L. and Piper Nigrum L. to COVID-19 associated receptors ACE2, spike protein RBD, and TMPRSS2. ChemRxiv 2020.
[117] 
Laporte M, Naesens L. Airway proteases: An emerging drug target for influenza and other respiratory virus infections. Curr Opin Virol  2017; 24: 16-24.
[http://dx.doi.org/10.1016/j.coviro.2017.03.018] [PMID:  28414992] 
[118] 
Kalyaanamoorthy S, Chen YPP. Structure-based drug design to augment hit discovery. Drug Discov Today  2011; 16(17-18): 831-9.
[http://dx.doi.org/10.1016/j.drudis.2011.07.006] [PMID:  21810482] 
[119] 
Silva LR, da Silva Santos-Júnior PF, de Andrade Brandão J, et al. Druggable targets from coronaviruses for designing new antiviral drugs. Bioorg Med Chem  2020; 28(22)115745
[120] 
Lima AN, Philot EA, Trossini GHG, Scott LPB, Maltarollo VG,
 Honorio KM. Use of machine learning approaches for novel drug
 discovery. Expert Opin Drug Discov. 2016; 11(3): 225-39.
[http://dx.doi.org/10.1517/17460441.2016.1146250] [PMID: 26814169] 
Rights & Permissions Print Cite
Article Metrics
33
2
Journal Information
For Authors
For Editors
For Reviewers
Explore Articles
Open Access
Open Access Articles
For Visitors
DOI https://dx.doi.org/10.2174/1389450122666210809090909	Print ISSN 1389-4501
Publisher Name Bentham Science Publisher	Online ISSN 1873-5592
Current Drug Targets

Molecular Modeling Targeting Transmembrane Serine Protease 2 (TMPRSS2) as an Alternative Drug Target Against Coronaviruses

Abstract Play Pause

Graphical Abstract

Related Journals

Related Books

Abstract
